Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 26, 2023, Calliditas Therapeutics announced the availability of its 2022 Annual Report on the company's website. The report provides insights into the company's performance, including developments in their lead product, Nefecon, which received FDA accelerated approval as TARPEYO® and conditional marketing authorization in the EU as Kinpeygo®. Additionally, Calliditas is advancing clinical trials for its NOX inhibitor product candidate, setanaxib, targeting primary biliary cholangitis and head & neck cancer. Contact for investor relations is Åsa Hillsten, available via phone or email. The company cautioned that the report contains forward-looking statements that are subject to risks and uncertainties regarding future performance.
Calliditas Therapeutics (NASDAQ: CALT, CALTX) announced its participation in two upcoming investor conferences. The first is the Guggenheim Genomic Medicines and Rare Disease Days Conference on April 3, 2023, in New York, featuring a fireside chat with CEO Renee Aguiar-Lucander and a KOL panel on IgA nephropathy treatment. The second event is the Kempen Life Sciences Conference in Amsterdam on April 25-26, 2023. Both conferences will include one-on-one meetings with investors, emphasizing Calliditas' commitment to developing innovative therapies for renal and hepatic diseases.
Everest Medicines announced that its partner Calliditas Therapeutics reported positive topline results from the Phase 3 clinical trial NefIgArd, evaluating Nefecon in patients with primary IgA nephropathy (IgAN). The trial met its primary endpoint, showing a statistically significant improvement in estimated glomerular filtration rate (eGFR) with Nefecon compared to placebo (p 0.0001). Results indicated an average eGFR increase of 5.05 mL/min/1.73 m